William (Wes) Salomon, PhD

Director, Delivery Biology at Tessera Therapeutics

William “Wes” Salomon, PhD has been in the field of RNA therapeutics and research for over 15 years. Dr. Salomon was one of the first employees at RXi Pharmaceuticals where he co-discovered their “self-delivering” RNAi platform. He left RXi to earn a doctoral degree in Biochemistry at the University of Massachusetts Medical School studying under Philip Zamore, PhD. His doctoral research focused on the mechanism of Argonaute proteins and the RNAi pathway to which it was published in Cell and named “Paper of the Year” by the Oligonucleotide Therapeutics Society in 2016. Dr. Salomon continued his career in the biotech industry at Intellia Therapeutics as a Principal Scientist evaluating new gene editing technologies and advancing the company’s understanding of the kinetics CRISPR-Cas9 editing when delivered by LNPs. He is currently the Director of Delivery Biology at Tessera Therapeutics where his team translates Gene Writer platform technologies into therapeutically relevant delivery models that will support Tessera’s therapeutic programs.